11.10.2024  22:00:00 Zm. +0,0500 Wolumen Bid00:00:00 Ask00:00:00 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
11,3800USD +0,44% 4,22 mln
Obrót: 31,96 mln
11,3200Wolumen Bid: 300 11,4200Wolumen Ask: 200 13,58 mldUSD 4,22% 227,60

Opis działalności

Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India.
 

Zarząd & Rada nadzorcza

CEO
Scott A. Smith
Zarząd
Sanjeev Narula, Rajiv Malik, Robert J. Coury
Rada nadzorcza
Robert J. Coury, W. Don Cornwell, JoEllen Lyons Dillon, Elisha W. Finney, Leo Groothuis, Melina Higgins, James Kilts, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish, Scott A. Smith, Pauline van der Meer Mohr
 

Dane firmy

Nazwa: Viatris Inc.
Adres: 1000 Mylan Boulevard, Canonsburg,Pennsylvania, 15317, USA
Telefon: +1-724-514-1800
Fax: -
E-mail: -
Internet: https://www.viatris.com/en
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: -
Data IPO: 16.11.2020

Relacje inwestorskie

Nazwa: Bill Szablewski
Telefon: +1-412-707-2866
Fax: -
E-mail: InvestorRelations@viatris.com

Główni akcjonariusze

Inne
 
55,73%
Vanguard Group Inc
 
11,94%
BlackRock Inc.
 
7,75%
Davis Selected Advisers, LP
 
5,26%
State Street Corporation
 
5,20%
Price T Rowe Associates Inc Md
 
4,15%
Invesco Ltd.
 
2,53%
Geode Capital Management, LLC
 
2,30%
Pacer Advisors Inc
 
1,75%
Inne
 
3,39%